Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2‐Year Clinical Trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2‐Year Clinical Trial

Published:2019-10-14 Issue:12 Volume:34 Page:2220-2228
ISSN:0884-0431
Container-title:Journal of Bone and Mineral Research
language:en
Short-container-title:J Bone Miner Res

Author:

Anastasilakis Athanasios D¹^ORCID,Papapoulos Socrates E²^ORCID,Polyzos Stergios A³^ORCID,Appelman‐Dijkstra Natasha M²,Makras Polyzois⁴^ORCID

Affiliation:

1. Department of Endocrinology424 General Military Hospital Thessaloniki Greece

2. Center for Bone Quality, Department of Internal Medicine, Section of EndocrinologyLeiden University Medical Center Leiden The Netherlands

3. First Department of Pharmacology, Faculty of MedicineAristotle University of Thessaloniki Thessaloniki Greece

4. Department of Endocrinology and Diabetes and Department of Medical Research251 Hellenic Air Force & VA General Hospital Athens Greece

Publisher

Wiley

Subject

Orthopedics and Sports Medicine,Endocrinology, Diabetes and Metabolism

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jbmr.3853

Reference46 articles.

1. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension

2. Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass

3. Observations following discontinuation of long-term denosumab therapy

4. Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases

5. Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension

Cited by 112 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The use of denosumab in osteoporosis – an update on efficacy and drug safety;Expert Opinion on Drug Safety;2024-09-11

2. One versus 2 years of alendronate following denosumab: the CARD extension;Osteoporosis International;2024-08-07

3. Treatment Sequence for Osteoporosis;Endocrine Practice;2024-05

4. Three-year effect of bisphosphonates on bone mineral density after denosumab withdrawal: observations from a real-world study;JBMR Plus;2024-04-30

5. Zoledronate After Denosumab Discontinuation: Is Repeated Administrations More Effective Than Single Infusion?;The Journal of Clinical Endocrinology & Metabolism;2024-04-13

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3